BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15449129)

  • 1. Oral alendronate treatment for polyostotic fibrous dysplasia: a case report.
    Kitagawa Y; Tamai K; Ito H
    J Orthop Sci; 2004; 9(5):521-5. PubMed ID: 15449129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral bisphosphonates in polyostotic fibrous dysplasia.
    Khadilkar VV; Khadilkar AV; Maskati GB
    Indian Pediatr; 2003 Sep; 40(9):894-6. PubMed ID: 14530553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alendronate therapy in polyostotic fibrous dysplasia presenting with pathologic fracture.
    Jayaraman M; Karikumar K; Verma A; Modi KD
    Am J Orthop (Belle Mead NJ); 2011 Mar; 40(3):E48-50. PubMed ID: 21720608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate therapy in polyostotic fibrous dysplasia.
    Kumar S
    Indian Pediatr; 2004 Oct; 41(10):1069-70. PubMed ID: 15523142
    [No Abstract]   [Full Text] [Related]  

  • 5. Fibrous dysplasia of the craniofacial bones.
    Lai WS; Lee JC
    J Am Osteopath Assoc; 2013 Aug; 113(8):641. PubMed ID: 23918916
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
    Plotkin H; Rauch F; Zeitlin L; Munns C; Travers R; Glorieux FH
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4569-75. PubMed ID: 14557424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate therapy in fibrous dysplasia.
    Lane JM; Khan SN; O'Connor WJ; Nydick M; Hommen JP; Schneider R; Tomin E; Brand J; Curtin J
    Clin Orthop Relat Res; 2001 Jan; (382):6-12. PubMed ID: 11154006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alendronate and pharmacological doses of 1alpha OHD3 therapy in a patient with McCune-Albright syndrome and accompanying hypophosphatemia.
    Yamamoto T; Ozono K; Shima M; Yoshikawa H; Okada S
    J Bone Miner Metab; 2002; 20(3):170-3. PubMed ID: 11984700
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
    Pfeilschifter J; Ziegler R
    Med Klin (Munich); 1998 Jun; 93(6):352-9. PubMed ID: 9662942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of polyostotic fibrous dysplasia].
    Klempous J; Kuźniar J; Sztuka A; Jaworska M
    Wiad Lek; 2006; 59(1-2):125-7. PubMed ID: 16646308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood.
    Chan B; Zacharin M
    J Pediatr Endocrinol Metab; 2006 Jan; 19(1):75-80. PubMed ID: 16509531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
    Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
    J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypophosphatemic rickets and osteomalacia in polyostotic fibrous dysplasia.
    Chattopadhyay A; Bhansali A; Mohanty SK; Khandelwal N; Mathur SK; Dash RJ
    J Pediatr Endocrinol Metab; 2003; 16(6):893-6. PubMed ID: 12948303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome.
    Zacharin M; O'Sullivan M
    J Pediatr; 2000 Sep; 137(3):403-9. PubMed ID: 10969268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Polyostotic fibrous dyplasia: a case report of a diffuse form with hemimelic predominance].
    Benbouazza K; Hassikou H; Guédira N; Abdelhafid E; Hajjaj-Hassouni N
    Rev Chir Orthop Reparatrice Appar Mot; 2002 Oct; 88(6):620-4. PubMed ID: 12447132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis.
    Heijckmann AC; Juttmann JR; Wolffenbuttel BH
    Neth J Med; 2002 Sep; 60(8):315-9. PubMed ID: 12481878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of oral alendronate therapy in an elderly patient with polyostotic fibrous dysplasia: A case report.
    Li GD; Ogose A; Hotta T; Kawashima H; Ariizumi T; Xu Y; Endo N
    Oncol Lett; 2011 Nov; 2(6):1239-1242. PubMed ID: 22848294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
    Lala R; Matarazzo P; Bertelloni S; Buzi F; Rigon F; de Sanctis C
    Acta Paediatr; 2000 Feb; 89(2):188-93. PubMed ID: 10709889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of high-dose oral bisphosphonate therapy for symptomatic fibrous dysplasia of the skull.
    Chao K; Katznelson L
    J Neurosurg; 2008 Nov; 109(5):889-92. PubMed ID: 18976079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate treatment in polyostotic fibrous dysplasia of the cranium: case report and literature review.
    Mansoori LS; Catel CP; Rothman MS
    Endocr Pract; 2010; 16(5):851-4. PubMed ID: 20570808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.